Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT

M. Viganò, C. Vener, P. Lampertico, C. Annaloro, C. Pichoud, F. Zoulim, F. Facchetti, F. Poli, M. Scalamogna, G. Lambertenghi Deliliers, M. Colombo

Research output: Contribution to journalArticlepeer-review

Abstract

Allogeneic hematopoietic SCT (HSCT) increases the risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen (HBsAg) carriers but the incidence, risk factors and course of HBV reactivation after HSCT in HBsAg-negative/anti-hepatitis B core antigen (anti-HBc)-positive recipients are not well known. A total of 50 HBsAg-negative/anti-HBc-positive HSCT recipients with onco-hematological diseases, underwent sequential clinical and laboratory examinations, including serum HBsAg, during follow-up. Serum HBV DNA collected at HSCT was retrospectively amplified by a sensitive PCR assay. During 17 months of follow-up, six (12%) patients had seroreverted to HBsAg, 7-32 months after HSCT, with 1- and 5-year cumulative rates of 13 and 22%. HBsAg seroreversion was associated with serum HBeAg higher than 8 log 10 copies per ml HBV DNA and a 1.5 to 36 fold increase of serum alanine aminotransferase leading to HBeAg-positive chronic hepatitis B in all patients. Patients with chronic onco-hematological disease and long-lasting immunosuppression following HSCT had a higher risk of HBsAg seroreversion independently of serum HBV DNA levels at HSCT. HBsAg-negative/anti-HBc-positive HSCT recipients with chronic onco-hematological disease carry a significant risk of HBsAg seroreversion and HBeAg-positive chronic hepatitis B, independently of serum levels of HBV DNA at transplantation.

Original languageEnglish
Pages (from-to)125-131
Number of pages7
JournalBone Marrow Transplantation
Volume46
Issue number1
DOIs
Publication statusPublished - Jan 2011

Keywords

  • BMT
  • HBsAg
  • HBVDNA
  • immunosuppression
  • stem cells

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT'. Together they form a unique fingerprint.

Cite this